




Study with the several resources on Docsity
Earn points by helping other students or get them with a premium plan
Prepare for your exams
Study with the several resources on Docsity
Earn points to download
Earn points by helping other students or get them with a premium plan
Case Presentation: Heart Failure
Typology: Exams
1 / 8
This page cannot be seen from the preview
Don't miss anything!





Definition of Heart Failure & Symptoms - A syndrome caused by cardiac dysfunction generally resulting from myocardial muscle dysfunction or loss. It is characterized by left ventricular dilatation or hypertrophy and leads to neurohormonal and circulatory abnormalities and characteristic symptoms including fluid retention, shortness of breath, and fatigue (especially on exertion). Left untreated, it is usually progressive at the levels of cardiac function & clinical symptoms. Severity of clinical symptoms may vary substantial during course of the disease process & may not correlate with changes in underlying cardiac function. Heart Failure - Physiological Characteristics - In physiological terms, HF is characterized by elevated cardiac filling pressure (this is to achieve adequate cardiac output and includes atrium & ventricle) OR inadequate peripheral oxygen delivery, at rest or during stress, caused by cardiac dysfunction (low cardiac output) 2 Categories of HF -
CXR, EKG, Labs Further Evaluation aimed at etiology, prognosis & therapeutic plan: Echo w/doppler, catheterization Other Studies: patch Signs and Symptoms of Left Heart Failure - 2 categories of signs/symptoms: Reduced CO: fatigue, impaired mentation, reduced BP, reduced pulse pressure, cool skin LV enlargement & volume overload: symptoms of left heart failure, Apical S3 Gallop (very specific), displaced & diffuse PMI, systolic murmurs of AV valve regurgitation Signs and Symptoms of Left Heart Failure related to the Respiratory System - Pulmonary Congestion or Edema due to high LA pressure/volume overload Cause of Right Heart Failure and Pathophysiology - In CHF, the most common cause of Right Heart Failure is Left Heart Failure. Elevated left heart pressures eventually lead to an increase in PA pressure and pulmonary vascular resistance. This increases the afterload on the Right Ventricle. This, coupled with the underlying cause for the CHF (i.e. CAD or cardiomyopathy) lead to a failure of the RV, with RV enlargement, Tricuspid Valve incompetence, elevated RA pressure and signs & sx of venous hypertension & congestion Mean Pulmonary Artery Pressure vs. Left Atrial Pressure - PA pressure should always be higher because blood has to move from the Right to Left Pulmonary Hypertension Defintion - Mean PA Pressure >25 mm Hg Signs and Symptoms of Right Heart Failure - Related to elevated RA pressure and high venous pressure and venous congestion. Abdominal Discomfort, Anorexia, Weight Gain *(fluid), Jugular Venous Distention (very specific), Hepatojugular Reflux, Ankle Edema, Acites, Tender & Pulsitile Liver Jugular Venous Distention (JVD) - Most sensitive & specific sign of CHF Patient sit sat 45° and physician identifies Internal Jugular vein. Elevation is measured from at the level of the Sternal Notch and how far it extends vertically. Normal <5 cm Gives an estimate of the RA pressure in mm of H₂O. Strongest Predictors of Mortality in Hospitalized ADHF Patients -
Treatment of Hypertension to Prevent HF - Aggressive BP control decreases risk of new HF by 50% (56% in DM2) Aggressive BP control in patients with prior MI decreases risk of new HF by 80% KEY POINT: Managing Stages A & B is much more important than managing Stages C & D (needs to be done by PCP, once you get to HF specialist it's too late) [ACE Inhibitors & Beta Blockers] - ACE Inhibitors are recommended for prevention of patients at high risk for HF including those with CAD, PVD, stroke, or diabetes + another risk factor ACE Inhibitors and Beta Blockers are recommended for all patients with prior MI. Treatment of Post-MI Patients with ACE Inhibitors who have Asymptomatic LV Dysfunction - Management of Diastolic Heart Failure - Regulation of BP There is NO medication to treat Diastolic HF Management of Systolic Heart Failure - ACE Inhibitors Angiotensin Receptor Blockers (ARBs) Beta Blockers ACE Inhibitors - Recommended for symptomatic and asymptomatic patients with an LVEF ≤40%. Applies to both post-MI and non-post-MI patients. Many studies show ACEI decrease mortality in both asymptomatic and symptomatic patients. The more advanced the HF is, the more effect the ACEI has. Lisinopril - Popular ACEI because it is $4 and only has to be taken 1x/day (good for compliance) Substitutes for ACEI - In patients who cannot tolerate ACE inhibitors due to cough, Angiotensin Receptor Blockers (ARBs) are recommended. The combination of Hydralazine and an Oral Nitrate may be considered in such patients not tolerating ARBs. Patients intolerant to ACEI from hyperkalemia or renal insufficiency are likely experience same side effects with ARBs. In these cases, the combination of hydralazine & an oral nitrate should be considered.
Beta Blockers & Reduced LVEF - Recommended for symptomatic and asymptomatic patients with LVEF ≤40%. Applies to both post-MI and non-post-MI patients. One of best medications for HF. Beta Blockers vs. ARBs & ACEI - ARBCs & ACEI decrease incidence of CHF Beta Blockers decrease incidence of CHF and sudden cardiac death Beta Blockers & Recent Decompensation - Beta blocker therapy is recommended for patients with a recent decompensation of HF after optimization of volume status & successful d/c of IV diuretics & vasoactive agents. (If you give it right away EF will go down & they will need to be intubated). Whenever possible, beta blocker therapy should be initiated in the hospital at a low dose prior to discharge of stable patients. [Beta Blockers & Symptomatic Exacerbation] - Continuation of therapy is recommended in most patients experiencing a symptomatic exacerbation of HF during chronic maintenance treatment, unless they develop cardiogenic shock, refractory volume overload, or symptomatic bradycardia Beta Blockers & Concomitant Disease - Beta Blocker therapy is recommended in most patients with HF and reduced LVEF, even if there is concomitant diabetes, COPD or PVD. Use with caution in patients with diabetes w/recurrent hypoglycemia or asthma (use β₁) or resting limb ischemia. Use w/considerable caution in patients w/marked bradycardia or hypotension. Not recommended in patients with asthma with active bronchospasm. Beta Blockers & Preserved LVEF - Beta Blocker treatment is recommended in patients with HF and preserved LVEF in patients who have prior MI, Hypertension, or Atrial Fibrillation requiring control of ventricular rate. Beta Blockers & ACEI in the Elderly - Beta Blockers and ACEI therapy is recommended as standard therapy in all elderly patients with HF due to LV systolic dysfunction. In the absence of contraindications, these therapies are also recommended in the very elderly (>age 80). Beta Blocker Overview -
Loop Diuretics rather than thiazide-type diuretics are typically necessary to restore normal volume status in patients with HF. No decrease in mortality or improvement in outcome. (all drugs before this in this lecture do decrease mortality) Loop Diuretics (Drugs) - Furosemide - most common Bumetanide - better absorption Torsemide - longer acting; greater decrease in morbidity Ethacrynic Acid - lack of salt? (patch) Potassium-Sparing Diurectics - EBM shows decreased mortality: Spironolactone Eplerenone Others (not mentioned): Amiloride Triamterene Device Therapy: Prophylactic Implantable Cardioverter Defibrillator (ICD) Placement & 1st study results - Should be considered in patients with an LVEF ≤35% and mild to moderate HF symptoms whether of ischemic or non-ischemic etiology. Should be considered in patients who are undergoing implantation of a biventricular pacing device. 1st Study: Decrease mortality by 15% compare to conventional therapy. Study of Amiodarone vs. ICD vs. Placebo - Amiodarone & Placebo overlap, which shows that Antiarrhythmic therapy w/Amiodarone is not preventing sudden cardiac death. Incidence of sudden cardiac death decreased by 5%. Discrepancy in this stat and last notecard (15% reduction) due to the 2nd/more recent study having patients on Beta Blockers, which decrease incidence of sudden cardiac death. Only decreases mortality, NOT morbidity Device Therapy: Biventricular Pacing - Recommended for patients with all of the following: Sinus Rhythm A widened QRS interval (≥120 ms) Severe LV systolic dysfunction Persistent, moderate-to-severe HF (Class III) despite optimal medical therapy. Improves functional class significantly, quality of life, AND decreases morbidity AND mortality.
Stages A-D and Corresponding Treatments (Diagram) - He did read through all this Prognosis - Annual mortality rate depends on patients symptoms & LV function. 5% mortality in patients w/mild sx & mild decrease in LV function. 30-50% in patients with advanced LV dysfunction & severe symptoms. 40-50% of death is due to SCD Stage D Therapy - Cardiac Transplant 1 year survival 90% 5 year survival 70% Problem is there aren't enough hearts. HeartMate I vs. HeartMate II - HM II is the only one used now